Hauser Barbara, Alonso Nerea, Riches Philip L
Rheumatic Disease Unit, Western General Hospital, NHS Lothian, Edinburgh EH4 2XU, UK.
Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
J Clin Med. 2021 Apr 1;10(7):1403. doi: 10.3390/jcm10071403.
Teriparatide has proven effective in reducing both vertebral and non-vertebral fractures in clinical trials of post-menopausal and glucocorticoid-induced osteoporosis. Widespread adoption of Teriparatide over the last two decades means that there is now substantial experience of its use in routine clinical practice, which is summarized in this paper. Extensive real-world experience of Teriparatide in post-menopausal osteoporosis confirms the fracture and bone density benefits seen in clinical trials, with similar outcomes identified also in male and glucocorticoid-induced osteoporosis. Conversely, very limited experience has been reported in pre-menopausal osteoporosis or in the use of Teriparatide in combination with other therapies. Surveillance studies have identified no safety signals relating to the possible association of Teriparatide with osteosarcoma. We also review the evidence for predicting response to Teriparatide in order to inform the debate on where best to use Teriparatide in an increasingly crowded therapeutic landscape.
在绝经后和糖皮质激素诱导的骨质疏松症的临床试验中，特立帕肽已被证明在减少椎体和非椎体骨折方面有效。在过去二十年中，特立帕肽的广泛应用意味着现在在常规临床实践中有大量使用经验，本文对此进行了总结。特立帕肽在绝经后骨质疏松症方面的广泛真实世界经验证实了临床试验中所见的骨折和骨密度益处，在男性和糖皮质激素诱导的骨质疏松症中也发现了类似结果。相反，关于绝经前骨质疏松症或特立帕肽与其他疗法联合使用的经验报道非常有限。监测研究未发现与特立帕肽可能与骨肉瘤相关的安全信号。我们还回顾了预测对特立帕肽反应的证据，以便在日益拥挤的治疗领域中为关于特立帕肽最佳使用位置的辩论提供信息。
